Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 238

1.

Brentuximab Vedotin and ESHAP is Highly Effective as Second-Line Therapy for Hodgkin Lymphoma Patients (Long-Term Results of a Trial by the Spanish GELTAMO Group).

Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Piñana JL, Rodriguez A, Gutiérrez A, Domingo-Domenech E, Sánchez-González B, Rodriguez G, Lopez J, Moreno M, Rodríguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C.

Ann Oncol. 2019 Jan 18. doi: 10.1093/annonc/mdz009. [Epub ahead of print]

PMID:
30657848
2.

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.

Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, Vangsted AJ, Vogel U, Kruszewski M, Subocz E, Buda G, Iskierka-Jażdżewska E, Ríos R, Merz M, Schöttker B, Mazur G, Perrial E, Martinez-Lopez J, Butterbach K, García Sanz R, Goldschmidt H, Brenner H, Jamroziak K, Reis RM, Kadar K, Dumontet C, Wątek M, Haastrup EK, Helbig G, Jurczyszyn A, Jerez A, Varkonyi J, Barington T, Grzasko N, Zaucha JM, Andersen V, Zawirska D, Canzian F.

Leuk Lymphoma. 2019 Jan 11:1-9. doi: 10.1080/10428194.2018.1551536. [Epub ahead of print]

PMID:
30633655
3.

Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma.

Navarro-Bailón A, Jiménez C, Alonso-Álvarez S, Alcoceba M, González-Calle V, Chillón MC, García-Álvarez M, Prieto I, Medina A, González M, Caballero MD, Blanco Ó, Díaz LG, García-Sanz R, Sarasquete ME.

Hematol Oncol. 2018 Dec 13. doi: 10.1002/hon.2570. [Epub ahead of print] No abstract available.

PMID:
30548996
4.

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, García-Sánchez O, Corral-Mateos A, Burgos L, Blanco E, Hernández-Martín J, Pontes R, Díez-Campelo M, Millacoy P, Rodríguez-Otero P, Prosper F, Merino J, Vidriales MB, García-Sanz R, Romero A, Palomera L, Ríos-Tamayo R, Pérez-Andrés M, Blanco JF, González M, van Dongen JJM, Durie B, Mateos MV, San-Miguel J, Orfao A; EuroFlow consortium.

Blood Cancer J. 2018 Nov 19;8(12):117. doi: 10.1038/s41408-018-0153-9.

5.

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018.

6.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review.

PMID:
29958569
7.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J.

Haematologica. 2018 Nov;103(11):e544-e548. doi: 10.3324/haematol.2018.188839. Epub 2018 Jun 28. No abstract available.

8.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

9.

A safety profile of medications used to treat Waldenström's macroglobulinemia.

García-Sanz R, Jiménez C, González De La Calle V, Sarasquete ME.

Expert Opin Drug Saf. 2018 Jun;17(6):609-621. doi: 10.1080/14740338.2018.1477936. Epub 2018 Jun 6. Review.

PMID:
29768934
10.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC.

Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15.

11.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.

Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G.

J Med Econ. 2018 May;21(5):525-536. doi: 10.1080/13696998.2018.1445634. Epub 2018 Mar 5.

PMID:
29480139
12.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD.

Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.

PMID:
29429912
13.

Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.

Jiménez C, Prieto-Conde MI, García-Álvarez M, Alcoceba M, Escalante F, Chillón MDC, García de Coca A, Balanzategui A, Cantalapiedra A, Aguilar C, Corral R, González-López T, Marín LA, Bárez A, Puig N, García-Mateo A, Gutiérrez NC, Sarasquete ME, González M, García-Sanz R.

Ann Hematol. 2018 Mar;97(3):475-484. doi: 10.1007/s00277-017-3207-3. Epub 2018 Jan 20.

PMID:
29353304
14.

Current Status of Cardio-Oncology in Spain: A National Multidisciplinary Survey.

Martín-García A, Mitroi C, García Sanz R, Santaballa Bertrán A, Arenas M, López-Fernández T; Spanish National Cardio-Oncology Working Group.

Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):84-86. doi: 10.1016/j.rec.2017.11.002. Epub 2017 Dec 6. English, Spanish. No abstract available.

PMID:
29203166
15.

From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.

Jiménez C, Alonso-Álvarez S, Alcoceba M, Ordóñez GR, García-Álvarez M, Prieto-Conde MI, Chillón MC, Balanzategui A, Corral R, Marín LA, Gutiérrez NC, Puig N, Sarasquete ME, González M, García-Sanz R.

Blood Cancer J. 2017 Aug 25;7(8):e591. doi: 10.1038/bcj.2017.72.

16.

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.

Rojas EA, Corchete LA, San-Segundo L, Martínez-Blanch JF, Codoñer FM, Paíno T, Puig N, García-Sanz R, Mateos MV, Ocio EM, Misiewicz-Krzeminska I, Gutiérrez NC.

Clin Cancer Res. 2017 Nov 1;23(21):6602-6615. doi: 10.1158/1078-0432.CCR-17-0678. Epub 2017 Aug 8.

17.

Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.

Chillón MC, Jiménez C, García-Sanz R, Alcoceba M, Prieto I, García-Alvarez M, Antón A, Maldonado R, Hernández-Ruano M, González M, Gutiérrez NC, Sarasquete ME.

Ann Hematol. 2017 Oct;96(10):1699-1705. doi: 10.1007/s00277-017-3083-x. Epub 2017 Aug 2.

PMID:
28770277
18.

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.

Quwaider D, Corchete LA, Misiewicz-Krzeminska I, Sarasquete ME, Pérez JJ, Krzeminski P, Puig N, Mateos MV, García-Sanz R, Herrero AB, Gutiérrez NC.

J Hematol Oncol. 2017 Apr 18;10(1):92. doi: 10.1186/s13045-017-0461-8.

19.

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations.

López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P, Velasco Del Castillo S, López de Sá Areses E, Barreiro-Pérez M, Hinojar Baydes R, Pérez de Isla L, Valbuena López SC, Dalmau González-Gallarza R, Calvo-Iglesias F, González Ferrer JJ, Castro Fernández A, González-Caballero E, Mitroi C, Arenas M, Virizuela Echaburu JA, Marco Vera P, Íñiguez Romo A, Zamorano JL, Plana Gómez JC, López Sendón Henchel JL.

Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):474-486. doi: 10.1016/j.rec.2016.12.041. Epub 2017 Mar 18. Review. English, Spanish.

PMID:
28330818
20.

Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.

Andrade-Campos M, Murillo-Flórez I, García-Sanz R, Giraldo P.

Clin Chem Lab Med. 2017 Aug 28;55(10):1598-1604. doi: 10.1515/cclm-2016-0748.

PMID:
28284031

Supplemental Content

Loading ...
Support Center